- Home
- DXR vs ATRA Comparison
DXR vs ATRA Comparison
Compare DXR & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- ATRA
- Stock Information
- Founded
- DXR 1970
- ATRA 2012
- Country
- DXR United States
- ATRA United States
- Employees
- DXR N/A
- ATRA N/A
- Industry
- DXR Medical/Dental Instruments
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXR Health Care
- ATRA Health Care
- Exchange
- DXR Nasdaq
- ATRA Nasdaq
- Market Cap
- DXR 46.1M
- ATRA 51.1M
- IPO Year
- DXR N/A
- ATRA 2014
- Fundamental
- Price
- DXR $10.14
- ATRA $11.58
- Analyst Decision
- DXR Strong Buy
- ATRA Strong Buy
- Analyst Count
- DXR 1
- ATRA 4
- Target Price
- DXR $25.00
- ATRA $20.00
- AVG Volume (30 Days)
- DXR 3.2K
- ATRA 57.7K
- Earning Date
- DXR 01-01-0001
- ATRA 08-11-2025
- Dividend Yield
- DXR N/A
- ATRA N/A
- EPS Growth
- DXR 86.16
- ATRA N/A
- EPS
- DXR 0.11
- ATRA N/A
- Revenue
- DXR $119,714.00
- ATRA $199,732,000.00
- Revenue This Year
- DXR N/A
- ATRA N/A
- Revenue Next Year
- DXR N/A
- ATRA N/A
- P/E Ratio
- DXR $92.00
- ATRA N/A
- Revenue Growth
- DXR N/A
- ATRA 475.53
- 52 Week Low
- DXR $6.55
- ATRA $5.01
- 52 Week High
- DXR $10.23
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- DXR 65.31
- ATRA 66.87
- Support Level
- DXR $9.05
- ATRA $8.53
- Resistance Level
- DXR $9.90
- ATRA $13.46
- Average True Range (ATR)
- DXR 0.29
- ATRA 0.96
- MACD
- DXR 0.02
- ATRA 0.28
- Stochastic Oscillator
- DXR 100.00
- ATRA 62.65
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).